To determine the RP2D of MEN1611 when administered orally in combination with cetuximab to patients with PIK3CA mutated colorectal cancer failing irinotecan, oxaliplatin, 5-FU and anti-EGFR containing regimens.The primary purpose of this study for Step 1: MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01).Drugs used in chemotherapy, such as TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Binimetinib and palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The purose of this study is to determine how well binimetinib and palbociclib work compared to TAS-102 in treating patients with KRAS and NRAS mutation positive colorectal cancer that has spread to other places in the body or cannot be removed by surgery. A Study to Evaluate the Combination of Binimetinib and Palbociclib in Treating Patients with KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer.The purpose of this study is to evaluate the short-term outcomes and the quality of life (QOL) after cholecystectomy and hepatic artery infusion pump placement for localized unresectable colorectal liver metastases (CRLM). Patient Outcomes after Hepatic Artery Infusion Pump Placement.The purpose of this study is to evaluate the safety, effectiveness and drug/body interactions of the combination of MM-151, nal-IRI, 5-FU, and leucovorin for the treatment of RAS/RAF wild-type (genetic mutations), metastatic, colorectal cancer. A Study to Evaluate MM-151, Nal-IRI, 5-FU, and Leucovorin for RAS/RAF Wild-Type Metastatic Colorectal Cancer.Approximately 687 subjects will be randomized to one of the following treatment arms in a 2:1 ratio, fruquintinib plus BSC or placebo plus BSC. The purpose of this study is to compare the effectiveness and safety of fruquintinib plus best supportive care (BSC) versus placebo plus BSC in patients with refractory metastatic colorectal cancer (mCRC). Scottsdale/Phoenix, AZ Rochester, MN Jacksonville, FL A Global, Randomized, Placebo-controlled Phase 3 Study of Fruquintinib in Patients with Refractory Metastatic Colorectal Cancer.It is not yet known whether lower-dose or standard dose regorafenib is more effective in treating patients with colorectal cancer. Regorafenib may stop the growth of colorectal cancer by blocking the growth of new blood vessels necessary for tumor growth and by blocking some of the enzymes needed for cell growth. This randomized phase II trial studies how well lower-dose compared to standard dose regorafenib works in treating patients with colorectal cancer that has spread from the primary site (place where it started) to other places in the body and does not respond to treatment. Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer. ![]() The purpose of this study is to evaluate the clinical activity, safety and tolerability of etruma-based treatment combinations. A Study to Evaluate the Safety and Effectiveness of AB928-Based Treatment Combinations to Treat Patients with Metastatic Colorectal Cancer.This is a blinded study such that the Investigator and Subject will be blinded but AbbVie will be unblinded. FOLFIRI is a chemotherapy regimen of fluorouracil, leucovorin and irinotecan. This study seeks to evaluate the efficacy and tolerability of veliparib in combination with FOLFIRI +/- bevacizumab in previously untreated, metastatic adenocarcinoma of the colon or rectum. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |